No abstract

Drug actions can be improved by developing new drug delivery systems, such as the mucoadhesive system. These systems remain in close contact with the absorption tissue, the mucous membrane, releasing the drug at the action site leading to a bioavailability increase and both local and systemic effects. Mucoadhesion is currently explained by six theories: electronic, adsorption, wettability, diffusion, fracture and mechanical. Several in vitro and in vivo methodologies are proposed for studying its mechanisms. However, mucoadhesion is not yet well understood. The aim of this study was to review the mechanisms and theories involved in mucoadhesion, as well as to describe the most-used methodologies and polymers in mucoadhesive drug delivery systems.Uniterms: Mucoadhesion. Bioadhesion. Mucoadhesive systems. Drugs/delivery. O efeito de fármacos pode ser potencializado através do desenvolvimento de novos sistemas de liberação como os sistemas mucoadesivos. Estes sistemas permanecem em contato íntimo com o tecido de absorção, as mucosas, liberando o fármaco no local de ação, com o consequente aumento da biodisponibilidade, podendo promover efeitos locais e sistêmicos. A mucoadesão, atualmente, é explicada por seis teorias, a eletrônica, da adsorção, da molhabilidade, da difusão, da fratura e a mecânica. Para estudar seus mecanismos e quantificá-la, são propostas várias metodologias in vitro e in vivo. Porém, a mucoadesão ainda não é totalmente compreendida. Esse trabalho tem por objetivo revisar os mecanismos e as teorias envolvidas na mucoadesão, além de descrever as metodologias e os polímeros mais utilizados em sistemas mucoadesivos para liberação de fármacos.Unitermos: Mucoadesão. Bioadesão. Sistemas mucoadesivos. Fármacos/liberação.

No abstract

Alzheimer’s disease is a neurological disorder that results in cognitive and behavioral impairment. Conventional treatment strategies, such as acetylcholinesterase inhibitor drugs, often fail due to their poor solubility, lower bioavailability, and ineffective ability to cross the blood–brain barrier. Nanotechnological treatment methods, which involve the design, characterization, production, and application of nanoscale drug delivery systems, have been employed to optimize therapeutics. These nanotechnologies include polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, microemulsion, nanoemulsion, and liquid crystals. Each of these are promising tools for the delivery of therapeutic devices to the brain via various routes of administration, particularly the intranasal route. The objective of this study is to present a systematic review of nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease.